TABLE 2.
| Characteristic | WCK 6777 2 g (N = 6) | ERT 2 g (N = 6) | ZID 2 g (N = 6) | WCK 6777 4 g (N = 6) | ERT 3 g (N = 7) | ZID 3 g (N = 7) | WCK 6777 6 g (N = 6) | Placebo (N = 10) | All participants (N = 54) |
|---|---|---|---|---|---|---|---|---|---|
| Sex, n (%) | |||||||||
| Male | 4 (67) | 3 (50) | 4 (67) | 3 (50) | 5 (71) | 5 (71) | 4 (67) | 6 (60) | 34 (63) |
| Female | 2 (33) | 3 (50) | 2 (33) | 3 (50) | 2 (29) | 2 (29) | 2 (33) | 4 (40) | 20 (37) |
| Ethnicity, n (%) | |||||||||
| Not Hispanic or Latino | 4 (67) | 5 (83) | 6 (100) | 5 (83) | 5 (71) | 6 (86) | 6 (100) | 9 (90) | 46 (85) |
| Hispanic or Latino | 2 (33) | 1 (17) | 0 | 1 (17) | 2 (29) | 1 (14) | 0 | 1 (10) | 8 (15) |
| Race, n (%) | |||||||||
| Black or African American | 5 (83) | 4 (67) | 2 (33) | 1 (17) | 2 (29) | 2 (29) | 5 (83) | 7 (70) | 28 (52) |
| White | 0 | 2 (33) | 4 (67) | 5 (83) | 4 (57) | 5 (71) | 1 (17) | 2 (20) | 23 (43) |
| Other/multiracial/unknown | 1 (17) | 0 | 0 | 0 | 1 (14) | 0 | 0 | 1 (10) | 3 (6) |
| Age (years) | |||||||||
| Mean ± SD | 33.7 ± 7.3 | 35.2 ± 9.2 | 32.3 ± 9.5 | 33.2 ± 7.0 | 33.6 ± 7.9 | 37.3 ± 5.6 | 29.2 ± 9.0 | 30.7 ± 6.7 | 33.0 ± 7.6 |
| Height (cm) | |||||||||
| Mean ± SD | 177.0 ± 14.0 | 168.3 ± 9.0 | 176.5 ± 10.1 | 169.8 ± 9.0 | 175.3 ± 3.6 | 175.9 ± 7.3 | 177.5 ± 7.8 | 170.7 ± 12.2 |
173.7 ± 9.7 |
| Weight (kg) | |||||||||
| Mean ± SD | 84.5 ± 9.8 | 81.0 ± 8.8 | 77.7 ± 3.4 | 79.9 ± 12.1 | 73.3 ± 5.4 | 84.5 ± 10.9 | 75.1 ± 8.7 | 77.9 ± 8.4 | 79.1 ± 9.0 |
| BMI (kg/m2) | |||||||||
| Mean ± SD | 27.1 ± 2.9 | 28.6 ± 2.1 | 25.2 ± 3.4 | 27.6 ± 2.9 | 23.8 ± 1.6 | 27.3 ± 2.8 | 24.1 ± 4.4 | 26.9 ± 2.8 | 26.3 ± 3.2 |
a
BMI, body mass index; ERT, ertapenem; ZID, zidebactam; and WCK 6777, ertapenem/zidebactam.
b
Percentages are based on the number of participants randomized per cohort.